Search for: "Amylin Pharmaceuticals, Inc."
Results 1 - 20
of 51
Sort by Relevance
|
Sort by Date
12 May 2015, 2:04 pm
The following is a list of some of the Barclays Reverse Convertible Notes offered: CUSIP Issuer Product Name 06740JJL5 Barclays Reverse Convertible Notes linked to Wells Fargo & Co. 06740JTD2 Barclays Reverse Convertible Notes linked to Wells Fargo & Co. 06740PGR1 Barclays Reverse Convertible Notes linked to Wells Fargo & Co. 06741JZQ5 Barclays Reverse Convertible Notes linked to 3D Systems Corp 06741J5M7 Barclays Reverse Convertible Notes linked to 3D Systems Corp 06741J3Y3 Barclays… [read post]
Delaware: Enjoining Advance Notice Bylaws Requires Radical Shift in Director-Initiated Circumstances
13 Jan 2015, 2:54 am
Amylin Pharmaceuticals, Inc.) relied on by the plaintiff where ANBs were enjoined because of the occurrence, after expiration of the advance notice deadline, of material, unanticipated and Board- initiated changes in company circumstances. [read post]
15 Aug 2013, 8:41 am
("CHIC") of Virginia sued Amylin Pharmaceuticals, Inc. and Amylin Pharmaceuticals, LLC (collectively, "Amylin"), both of Los Angeles, California and Eli Lilly & Co. [read post]
1 Aug 2013, 9:29 am
The generic and brand names of the drugs in this family include: • Exenatide (Byetta & Bydureon) marketed by Bristol Myers-Squibb and Amylin Pharmaceuticals, Inc. [read post]
28 Jul 2013, 9:29 am
If you have a legal question or concern about a potential personal injury claim in Florida for a car accident, slip and fall at a store, mall or tourist attraction, or have a been hurt by a prescription diabetes drugs such as: Byetta (Manufactured by Amylin Pharmaceuticals, Inc.) [read post]
3 Jul 2013, 12:27 pm
Amylin Pharmaceuticals Inc. et al Court Case Number: 1:13-cv-01061-TWP-DMLFile Date: Tuesday, July 02, 2013Plaintiff: Consumer Health Information CorporationPlaintiff Counsel: James Dimos of Frost Brown Todd LLCDefendant: Amylin Pharmaceuticals Inc. [read post]
19 Apr 2013, 9:32 am
Amylin Pharmaceuticals, confirm that corporations, as a matter of process, should carefully consider and review whether proxy put and other similar change-of- control provisions in credit agreements and indentures are truly in the best interests of the stockholders. [read post]
4 Sep 2012, 7:31 am
But as she prepared to woo drug maker Amylin Pharmaceuticals Inc. last year, she was worried. [read post]
7 Aug 2012, 8:10 am
Ramnarine made more than $300,000 in illegal profits by misusing nonpublic information he obtained while helping Bristol-Myers Squibb evaluate whether to acquire three other pharmaceutical companies (Pharmasset Inc., Amylin Pharmaceuticals Inc., and ZymoGenetics Inc.). [read post]
24 May 2012, 6:15 am
Amylin Pharmaceuticals, Inc. [1] granting a motion to expedite a claim by Carl Icahn that Amylin's directors breached their fiduciary duties by not waiving Amylin's advance notice bylaw. [read post]
24 Apr 2012, 1:06 pm
Amylin Pharmaceuticals, Inc., C.A. [read post]
18 Apr 2012, 1:32 pm
Amylin Pharmaceuticals Inc., C.A. 7404-VCN (April 18, 2012) An advance notice bylaw requires stockholders to tell their company substantially in advance of a stockholders' meeting if they want to nominate someone to to be elected as a director at that upcoming meeting. [read post]
20 Mar 2012, 8:40 am
Supreme Court's decisions in eBay Inc. v. [read post]
29 Feb 2012, 9:05 am
Amylin Pharmaceuticals, Inc., 2011 U.S. [read post]
21 Feb 2012, 9:22 am
On the life sciences front, notably, the firm has represented Eli Lilly & Co. in a dispute with Amylin Pharmaceuticals Inc. over a new diabetes drug, winning the denial of a preliminary injunction that would have stood in the way of Eli Lilly’s marketing efforts. [read post]
12 Jul 2011, 6:59 am
In 2002, Lilly entered a collaboration agreement with Plaintiff Amylin Pharmaceuticals to sell Amylin’s type-2 diabetes treatment Byetta. [read post]
9 Jun 2011, 12:43 pm
Washington-based partners Thomas Barnett and Michael Imbroscio persuaded a San Diego federal judge to vacate a temporary restraining order granted to Amylin Pharmaceuticals Inc. and deny Amylin's motion for a preliminary injunction. [read post]
14 Nov 2010, 3:30 am
Dunbar, Senior Director, Intellectual Property and Legal Affairs at the Sanford-Burnham Institute for Medical Research; and Harry Leonhardt, Vice President, Deputy General Counsel/Corporate Governance at Amylin Pharmaceuticals, Inc. [read post]
24 Sep 2010, 1:22 pm
Patent No. 7,297,761 owned by Amylin Pharmaceuticals, Inc. and entitled PHARMACEUTICAL COMPOSITIONS CONTAINING EXENDINS. [read post]
6 Jan 2010, 2:05 pm
FDA Letter About Byetta Sent To Amilyn In October 2009; Drug Company Tries To Downplay, But Investors React When They Learn About It In December 2009 (Posted by Tom Lamb at DrugInjuryWatch.com) On October 30, 2009 Amylin Pharmaceuticals Inc. issued a press release, "BYETTA Approved for Expanded Use as First-Line Treatment for Type 2 Diabetes Prescribing Information Also Includes Updated Safety Information", in which they announced that the FDA had approved an… [read post]
